Comparable stake leader
Ethan Shen PhD
SEC ownership of YD Bio Ltd
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0002011674.
Disclosed value leader
Ethan Shen PhD
Comparable rows
10/19
Latest evidence
31 Mar 2026
- Public ticker
- YDES, YDESW on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- Ethan Shen PhD
- Latest 13D/G holder
- Ethan Shen PhD
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0002011674
- Issuer location
- Irving, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of YD Bio Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Ethan Shen PhD
Disclosed value leader
Ethan Shen PhD
Comparable rows
10/19
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 77%
9 rows are not safely comparable across share classes.
13D/G row: Ethan Shen PhD
Showing 1-8 of 19 holder rows.
Quick read
Ethan Shen PhD leads the comparable SEC ownership view at 77%.
10 of 19 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Ethan Shen PhD's linked filing trail.
Comparable ownership
Top 5
Ethan Shen PhD
77%
Shao-Ta Lu
0.08%
Bo-Xiang Zhang
0.04%
Kochi Chang
0%
GEODE CAPITAL MANAGEMENT, LLC
0.09%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 19 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Ethan Shen PhD |
13D/G
3/4/5
Ethan Shen · CEO, Director
|
77%
|
$663,552,584
54,345,011 shares
|
$0 | 17 Feb 2026 |
| Shao-Ta Lu |
3/4/5
Director
|
0.08%
|
$422,810
53,232 shares
|
— | 31 Mar 2026 |
| Bo-Xiang Zhang |
3/4/5
Chief Medical Officer, Director
|
0.04%
|
$379,608
31,141 shares
|
— | 18 Mar 2026 |
| Kochi Chang |
3/4/5
Director
|
0%
|
$25,367
2,081 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
0.09%
|
$463,817
60,236 shares
|
— | 31 Mar 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.03%
|
$149,765
19,450 shares
|
— | 31 Mar 2026 |
| UBS Group AG |
13F
Company
|
0.02%
|
$89,536
11,628 shares
|
— | 31 Mar 2026 |
| WOLVERINE ASSET MANAGEMENT LLC |
13F
Company
|
0.01%
|
$37,622
4,886 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 04 Jun 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to YD Bio Ltd. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Largest Forms 3/4/5 holder
Ethan Shen PhD
Net 12M change
$0
Latest report
31 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Ethan Shen PhD | CEO, Director | $441,824,938 | Mixed | 18 Mar 2026 | ||
| Shao-Ta Lu | Director | $422,810 | Mixed | 31 Mar 2026 | ||
| Bo-Xiang Zhang | Chief Medical Officer, Director | $379,608 | Mixed | 18 Mar 2026 | ||
| Kochi Chang | Director | $25,367 | Mixed | 31 Mar 2026 | ||
| Man Edmund Hen | Chief Financial Officer | Mixed | 18 Mar 2026 | |||
| Jerry Yin-Chia Lee | Director | Mixed | 18 Mar 2026 |
Recent insider transactions for YD Bio Ltd
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Shao-Ta Lu | YDES | Ordinary Shares | Options Exercise | 2,081 | 2,081 | 31 Mar 2026 | Direct | |||
| Shao-Ta Lu | YDES | Restricted Share Units | Options Exercise | 2,081 | 0 | 31 Mar 2026 | Direct | |||
| Shao-Ta Lu | YDES | Restricted Share Units | Award | 2,081 | 2,081 | 31 Mar 2026 | Direct | |||
| Kochi Chang | YDES | Ordinary Shares | Options Exercise | 2,081 | 2,081 | 31 Mar 2026 | Direct | |||
| Kochi Chang | YDES | Restricted Share Units | Options Exercise | 2,081 | 0 | 31 Mar 2026 | Direct | |||
| Kochi Chang | YDES | Restricted Share Units | Award | 2,081 | 2,081 | 31 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.